Background Gastroesophageal reflux disease (GERD) contributes to substantial medication use and costs worldwide. Economic evaluations provide insight into the value of healthcare, taking into account cost, quality, and benefits of particular treatments. Objectives Our objectives were to systematically review the existing literature to identify economic evaluations of GERD management strategies, to assess the scientific quality of these reports, and to summarize the economic outcomes of these evaluations. Methods We identified economic evaluations and cost studies of GERD management strategies by searching PubMed and the UK NHS Economic Evaluation Database via the Cochrane Library. Searching was restricted to articles in English-language journals from July 2003 to July 2013. Cost-identification articles were excluded from the final analysis. Results Eighteen articles were included in the final analysis; 61 % of these met all criteria for quality reporting. Overall, proton pump inhibitor (PPI) therapy was preferred (most effective and least costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high Helicobacter pylori prevalence ([40 %). Initial empiric PPI therapy (vs. initial endoscopy stratification or H. pylori testing) is likely the most costeffective initial strategy for patients with typical GERD symptoms. Surgery may be cost effective in patients with chronic GERD symptoms at time horizons of 3-10 years. Endoscopic anti-reflux procedures were not cost effective based on available data. Conclusions Further economic evaluations should adhere to standard reporting measures of cost estimates and outcomes, and should attempt to account for and compare the large heterogeneity of patient phenotypes and treatment effects seen with anti-reflux therapies.
Introduction
Gastroesophageal reflux disease (GERD) symptoms and sequelae cause considerable morbidity and contribute to substantial medication use and costs worldwide [1, 2] . In the USA alone, overall spending on all gastrointestinal diseases is estimated to be US$142 billion (year 2009 values) per year in direct and indirect costs [3] . GERD accounts for approximately US$15-20 billion of these direct and indirect costs [4] . A study in 1997 found that total unadjusted medical costs of GERD in a US health maintenance organization population (1,550 people with GERD) were US$2,089 higher than for controls; this corresponded to costs of US$471 attributable directly to GERD (inpatient, outpatient, and pharmacy costs) [5] . Factors contributing to GERD-related costs include direct costs (e.g., medication use, diagnostic testing, physician visits, and hospitalizations) and indirect costs (e.g., decreased quality of life, work absenteeism, and loss of productivity). It has been estimated that prescribed medications for GERD, primarily proton pump inhibitors (PPIs), account for more than 50 % of prescriptions for all digestive diseases, resulting in around US$10 billion in annual direct healthcare costs [1, 4] . In 2010, one PPI (esomeprazole) accounted for the most retail dollars ([US$5.2 billion) of all branded drugs sold in the USA [6] .
In light of the enormous healthcare burden attributed to GERD, numerous studies have evaluated cost, healthcare utilization, and cost effectiveness of differing management strategies. As economic evaluations are often used as the basis for practice guidelines and resource allocation, it is critical that reporting of data is appropriately scrutinized. The growing field of comparative effectiveness research also often uses cost considerations to determine thresholds of effectiveness. Recently, the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) developed the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) to guide quality reporting in economic evaluations [7] .
Our first objective was to systematically evaluate the existing literature to identify economic evaluations of GERD medical management strategies and assess the scientific quality of these reports using the CHEERS guidelines. Our second objective was to summarize the economic outcomes of the included studies.
Methods
We identified economic evaluations and cost studies of GERD medical management strategies by searching PubMed and the UK NHS Economic Evaluation Database via the Cochrane Library. Searching was restricted to articles in English-language journals from July 2003 to July 2013. The search strings for both databases were as follows:
PubMed: ((((((('' 
Inclusion/Exclusion Criteria
Abstracts from the articles identified by the initial search strategy were then analyzed for inclusion or exclusion.
Inclusion Criteria
Adult studies addressing management strategies for GERD in English-language journals were included; studies comparing medical to surgical management were also included. A study was included in the final analysis if it was considered to be an economic evaluation; that is, if it reported evidence on costs and endpoints for effectiveness or benefits.
Exclusion Criteria
Publications focused on Barrett's esophagus, diagnostic testing, only surgical or endoscopic therapy for GERD, dyspepsia, editorials, comments, letters to the editor, news, conference abstracts, and material published prior to 2003 were excluded from the analysis. Pediatric studies were also excluded. Cost-identification articles were excluded from the final analysis of quality and outcomes. A study was considered a cost-identification analysis if cost data were presented but were not related to the treatment effectiveness or benefits.
Review of Methodological Quality and Outcomes of Economic Evaluations
Included studies were assessed according to the CHEERS task force guidelines on good reporting practices for economic evaluations by two independent reviewers (AJG, DDF) [7] . The CHEERS checklist has been provided in the Appendix. Data for the economic evaluations were then abstracted and summarized according to the population studied and cost outcomes.
Results
The initial literature search identified 219 and 52 articles from PubMed and the Cochrane/NHS economic evaluation database, respectively (Fig. 1) . After exclusion criteria were applied and the results were combined, the abstracts and manuscripts (if necessary) of 58 articles were reviewed for initial inclusion in the final review. Of these, 35 (60 %) were excluded as they reported cost-identification outcomes without linking cost to effectiveness. An additional six articles were subsequently excluded as they did not involve any comparisons of the medical management of GERD (n = 4) or focused only on screening for Barrett's esophagus (n = 2). One additional article was obtained via expert opinion that was not identified with the literature search [8] . Thus, 18 articles were included in the final analysis [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] (Fig. 1) ; their general characteristics are shown in Table 1 .
The quality of the 18 articles, as assessed by the CHEERs guidelines, is shown in Table 2 . Of the 24 items, 11 articles (61 %) met all criteria for economic evaluation reporting [8-15, 18, 19, 21] . Only one did not explicitly identify the study as an economic evaluation in the title [16] . The majority of missing items were specific methods including mention of discount rates (n = 4) [16, [23] [24] [25] and study parameters (n = 2) [16, 25] . Three articles did not disclose funding sources [22] [23] [24] and four did not disclose conflicts of interest [17, 20, 22, 23] . Of these, two included neither disclosure of funding nor conflicts of interest [22, 23] .
Of the 18 included articles (Table 3) , three used a decision analysis [18, 22, 24] , nine used Markov modeling [9, 10, 12-14, 17, 20, 21, 23] , and five reported cost outcomes related to randomized trials [8, 11, 15, 16, 19] . Only one used a retrospective cohort design in assessing the incremental annualized healthcare costs of compliant and non-compliant PPI users [25] . Fifteen articles (78 %) included comparisons of different PPI strategies (n = 7, [16] [17] [18] [19] [20] [21] 23] ) or PPI therapy with surgery (n = 8, [8] [9] [10] [11] [12] [13] [14] [15] 24] ). Four articles compared PPI therapy with endoscopicbased management (either as a diagnostic or therapeutic strategy) [9, 16, 17, 22] . Of the 12 papers that used decision analysis or Markov models [9, 10, 12-14, 17, 18, 20-24] , nine were performed from a non-US societal or public health system perspective [9, 12-14, 17, 20, 21, 23, 24] . The majority of articles (n = 15) used a public healthcare system perspective (e.g., UK NHS, US Medicare) [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [19] [20] [21] [22] [23] . One study used an employer cost perspective [18] , one used a societal perspective [24] , and one used a thirdparty payer perspective [25] . More articles reported cost outcomes in US dollars (n = 7) than other individual currencies ( Table 1 ). The time horizons used in the decision and Markov models were highly variable ranging from 5 months [23] to a lifetime [8, 13, 14] . The economic outcomes for specific articles are summarized in Table 3 ; most studies reported outcomes as incremental cost effectiveness ratios (ICERs).
Proton Pump Inhibitor (PPI) Therapy Versus Surgery
Of the articles comparing PPI therapy to laparoscopic surgery, all studies except one concluded that surgery was cost effective when compared to long-term PPI therapy (ranging from 3 years to lifetime). For example, in the study by Goeree et al. [15] , laparoscopic Nissen fundoplication (LNF) had a primary outcome ICER of US$29,404 per QALY gained when compared to PPIs over a 3-year time horizon. However, this study's outcomes were very sensitive to QALY estimates. The base case used the Health Utility Index 3 survey as the primary utility measure [15] . In comparison, use of EQ-5D utility weights resulted in an ICER of US$76,310/QALY (LNF vs. PPIs) [15] . When a lifetime perspective was applied by Epstein Methods: no mention of discount rate 4 (22) [16, [23] [24] [25] Results: missing reporting of study parameters 2 (11) [16, 25] Methods: missing description of sampling uncertainty 1 (5) [24] Other: missing source of funding 3 (17) [22] [23] [24] Other: missing conflicts of interest disclosure 4 (22) [17, 20, [22] [23] [24] Effectiveness outcomes [22] were estimated from published literature: endoluminal plication failure rate = 10-20 %, radiofrequency coagulation failure rate = 20 %. PPI therapy was assumed to be effective (daily or twice daily) at initial decision node prior to endoluminal plication or radiofrequency coagulation et al., LNF had an ICER of US$4,385/QALY compared to PPI therapy [12] . However, modeling was based on only 1 year of data from the REFLUX trial and relied on assumptions of surgery durability [12] . The most recent study by Grant et al. used 5-year follow-up data from the REFLUX trial, which is a major strength compared with older studies that relied on assumptions of surgical durability [8] . They found that, although initially more costly, surgery is more likely to be cost effective as it provides better relief of GERD symptoms and improved quality of life.
There was one study that reported that PPI therapy was more effective and less costly than surgery at a 10-year time horizon [10] . It should be noted that this study's outcomes were sensitive to QALY estimates that were primarily derived from patients who had open (as opposed to laparoscopic) surgical fundoplication. Also, the probability estimates of symptom recurrence after surgery were derived from an older paper evaluating outcomes of Toupet fundoplication which showed 67 % recurrence of symptoms in \3 years after surgery [26] .
PPI Therapeutic Regimen Comparisons
In studies comparing different PPI therapeutic regimens, results differed based on the setting and comparisons. Moayyedi et al. found that empiric PPI therapy based on a structured questionnaire was cost effective [US$764/quality-adjusted life month (QALM) gained] compared with controls [19] . In an extensive Markov model evaluating seven different PPIs and a variety of treatment regimens, generic omeprazole (20-40 mg daily) was the least costly and most effective, and hence dominated all strategies [21] . Rabeprazole dominated all other PPIs except omeprazole and was found to have a favorable cost-effectiveness ratio when compared with omeprazole of £3.42 per symptomfree day [21] .
Empiric PPI Therapy Versus Endoscopic-Directed
Medical Therapy or Helicobacter pylori Testing Empiric esomeprazole therapy was found to be less costly per treated patient using data from a randomized trial comparing empiric PPI therapy (€88.34) and PPI treatment based on endoscopy (€127.06) [16] . Health-related quality of life (HR-QOL) improved in all patient groups but there was no significant difference between groups at both baseline and follow-up [16] . The authors noted that empiric treatment saved €38.72 per patient and could reduce the number of endoscopies by *90 % [16] . Helicobacter pylori prevalence was not determined in the trial [16] . In a population with high background prevalence of H. pylori infection (base-case estimate of 46 %), You et al.
determined that empiric PPI therapy cost more (US$2,158/ ulcer treated) than an initial test and treat strategy for H. pylori (US$1,778/ulcer treated) or early endoscopy (US$1,797/ulcer treated) than no therapy [17] . However, empiric PPI therapy was overall more effective as it resulted in the highest number of symptom-free patientyears as it can also improve dyspeptic symptoms associated with H. pylori infection [17] .
PPI Therapy Versus Endoscopic Therapy
One study was identified that compared PPI therapy to endoluminal plication (Endocinch TM ) or radiofrequency coagulation for GERD (Stretta TM procedure); PPI therapy was dominant (i.e., less costly and more effective) regardless of time as long as the cost of PPI therapy was below US$140/month or the cost of endoscopic therapy was over US$3,400 [22] .
PPIs Versus Histamine H 2 -Receptor Antagonists
Two studies compared PPIs with histamine H 2 -receptor antagonist (H 2 RA) treatment. Habu et al. developed a Markov model comparing initial PPI therapy and H 2 RA with escalating PPI therapy in patients with endoscopically confirmed reflux esophagitis versus no therapy [23] . Compared with no therapy, initial PPI therapy had an ICER of 211 Japanese yen (¥) per day without esophagitis. This was less costly (and more effective) than first using an H 2 RA (¥217/day without esophagitis compared with no intervention). Thresholds for cost effectiveness were not reported in the paper by Habu et al. You et al. also used Markov modeling to evaluate standard-dose PPI therapy with low-dose PPI and standard-dose H 2 RA therapy for healed esophagitis [20] . Standard-dose PPI therapy was less costly per QALY (US$905/QALY gained) than lowdose PPI (US$1,374/QALY gained) and H 2 RA treatment (US$1,633/QALY gained) [20] . Additionally both standard-dose PPI and low-dose PPI treatment dominated standard-dose H 2 RA treatment (with more symptom-free patient-years gained and a lower cost per patient). The results were due to a lower relapse probability with stronger therapy (standard-dose PPI) leading to overall lower long-term healthcare costs.
PPI Compliance and Effect on Healthcare Costs
One paper included in the review addressed the issue of PPI compliance and effect on healthcare costs. Gosselin et al. [25] found that patients compliant with PPI therapy had greater incremental healthcare cost savings than noncompliant patients (annual savings of US$3,261 vs. US$2,406) [25] .
Discussion
In this systematic review of economic evaluations of GERD medical management over the past decade, we identified 18 articles meeting strict inclusion criteria for analysis. PPI therapy was preferred (i.e., both more effective and less costly) as empiric therapy for patients with reflux symptoms, except in patient populations with high H. pylori prevalence, and this is reflected by clinical practice and guideline recommendations [27] . Although surgery is initially costly, many patients have good symptom control over time and therefore surgery may be cost effective compared to medical therapy over time periods modeled ranging from 3 years [15] to a lifetime [8] . Endoscopic anti-reflux procedures do not appear cost effective compared to medical therapy based on available data from studies that examined what are now largely obsolete procedures. Should more innovative endoscopic GERD management strategies be introduced and adopted, more economic research will be needed to evaluate their relative cost effectiveness.
As healthcare accounts for growing budgetary commitments worldwide, there has been an increased emphasis on evaluating therapies in terms of cost and quality. In turn, the research surrounding disease states often includes cost as a secondary outcome. Reporting of cost, however, is overly simplistic and does not necessarily imply value. Most of the articles that we initially identified were not included as they were simply cost-identification studies, and did not relate cost to actual benefit or effectiveness of therapy. Costidentification articles are a first and easy step to identify key cost components that can be used in subsequent economic evaluations. However, cost-identification results should not be overstated by drawing conclusions about the cost with actual effectiveness of therapy.
In light of the increased emphasis on cost, it is critical that research reporting cost outcomes is evaluated rigorously. Recently, the ISPOR taskforce provided guidance for evaluating quality of economic evaluations with release of the CHEERs checklist. Overall, around 60 % of the included articles met all CHEERs criteria. Those not meeting all of the CHEERs criteria mainly omitted method descriptions or disclosures of funding. As many cost studies involve sophisticated modeling techniques based on probability estimates and possible funding from pharmaceutical companies or device manufacturers, disclosure of funding sources is critical to ensure that readers can reliably assess any potential for bias. Investigators embarking on future research with cost outcomes should use the CHEERs checklist to guide study design and reporting of results. In turn, the criteria may help editors and reviewers ensure consistent reporting and identification of bias in economic evaluation research.
Numerous medications can be taken for reflux symptoms including antacids, H 2 RAs, and PPIs. Economic evaluations comparing medical therapies suggest that PPI use is more effective than treatment with an H 2 RA and less costly due to lower rates of symptom and esophagitis recurrence [20, 23] . As there is very little evidence that any one PPI is superior in terms of efficacy, use of the cheapest PPI available dominated specific PPI therapeutic regimens [21] . The most recent Technical Review on GERD from the American Gastroenterological Association reflected the superiority of PPI therapy over H 2 RAs [28] but did not specifically recommend one particular PPI formulation over others. A recent US population study using the National Ambulatory Medical Care Survey (NAMCS) found that both branded (esomeprazole) and generic (omeprazole) PPIs had a significant increase in use from 2002 to 2009 [29] . There is very little evidence that more expensive PPIs offer additional major benefits over less costly PPIs for most GERD patients, especially for initial therapy. Therefore, practitioners in countries or settings without fixed formularies should be encouraged to use the least costly PPI formulation.
Numerous studies included in this review compared medical and surgical therapy for GERD. Laparoscopic surgery was found to meet cost-effectiveness thresholds, especially if time horizons were between 3 and 10 years [8, [12] [13] [14] [15] , although one study showed PPIs to dominate surgery (less costly and more effective) within 10 years [10] . This difference is probably due to the quality-of-life estimates (utilities) [26] that were essentially the same for both surgical and medical therapy based on two older studies [26, 30] . The most recent study with impressive long-term patient follow-up (5 years) found that more patients randomized to early LNF (vs. medical therapy) had less frequent heartburn and regurgitation at 3 and 5 years' followup [8] . In addition, quality-of-life scores were greater in surgery patients at 5 years' follow-up [8] . Laparoscopic techniques to prevent acid reflux have very good long-term outcomes in select patients [8, 31, 32] and non-laparoscopic anti-reflux surgery was the primary therapy for many patients with GERD prior to the introduction of PPIs [31] . However, surgery rates for GERD have declined over time. In 2005, there were 15,737 Nissen fundoplication procedures performed in the USA [33] . Although this is still one of the most common anti-reflux procedures, its use had declined by 27 % from the late 1990s [33] . Patient and physician preferences have probably played a role in this trend towards less invasive (and mostly effective) medical treatment. However, the cost effectiveness of surgery should not be underestimated, especially in patients with a definite diagnosis of GERD that is truly refractory to optimized medical treatment, perhaps because of volume reflux. Based on this review, there is little economic evidence that endoscopic anti-reflux procedures or performing endoscopy prior to PPI therapy are cost-effective strategies. Further research is also needed to determine if other emerging technologies for GERD, such as a magnetic device for lower esophageal sphincter augmentation [34] , will be cost effective, assuming safety and efficacy are demonstrated before widespread clinical adoption.
Limitations of this review include the inability to pool data due to the different time horizons and comparisons made in individual studies. Thus, it is difficult to obtain pooled estimates of cost effectiveness based on published data. Economic modeling is based on assumptions and probability estimates that usually require sensitivity analyses to test model integrity. The articles included in this review did report robust sensitivity analyses. However, limitations of economic evaluations include the challenge of accounting for treatment effects in the wide variety of GERD patient phenotypes in a single study (e.g., classic/ typical reflux symptoms, reflux symptoms with mixed functional etiology, extra-esophageal reflux symptoms). The definition for efficacy used in the clinical trials and modeling may vary considerably in studies of GERD (e.g., global symptom scores [19] , disease-specific patientreported outcomes [8] , HR-QOL [10] , and symptom-free days [21] ). GERD is also a diagnosis that is sometimes given to patients as an explanation for a variety of upper gastrointestinal symptoms that, consequently, display a highly variable response to medical therapy. The models employed in the included literature assumed PPI prescribing is systematic and that patient compliance is substantial. In fact, in clinical practice, PPI prescriptions and subsequent PPI utilization have been found to be highly variable across settings [35] [36] [37] [38] [39] . The actual realized economic outcomes reported, especially regarding PPI therapy, are probably less than optimal in clinical practice.
In summary, this is the first systematic review of economic evaluations of GERD medical management. Any future evaluations should adhere to standard reporting measures so that readers can assess and compare quality of cost estimates and outcomes. Future economic evaluations of GERD medical management should also attempt to account for, and compare, different patient phenotypes and the large heterogeneity of treatment effects seen with antireflux therapy. In clinical practice, the primary focus should be on optimal care coordination of patients with reflux symptoms via cost-effective management strategies that are aligned with patient preferences [40] .
